Drug-eluting stents were associated with a lower rate of restenosis compared to bare metal stents (23.1% vs 48.8%) at 6 to 9 months follow-up.
Cohort (n=130)
No
Do drug-eluting stents reduce the incidence of restenosis compared to bare metal stents in patients undergoing coronary stenting?
Drug-eluting stents are associated with a lower rate of angiographic restenosis compared to bare metal stents at 6 to 9 months follow-up.
Absolute Event Rate: 23.1% vs 48.8%
BACKGROUND: Various studies have been performed throughout the world on the rate of restenosis using bare metal stents (BMS) and drug-eluting stents (DES). The prohibitive costs associated with DES generally dictate the type of stent used, especially in developing countries. Therefore, there was a need for a study to assess the effect of various risk factors on restenosis in BMS and DES in the Indian context. A study was performed in the premier institution of the Indian Armed Forces, the Army Hospital (Research and Referral), New Delhi, India, under the aegis of the Indian Council of Medical Research (New Delhi). The profile of patients in the armed forces is inherently diverse in terms of demography, ethnicity, genetics, etc, which reflects the diverse and varied nature of the population in India. METHODS AND RESULTS: A total of 130 patients were included in the present study. Follow-up after stent implantation was scheduled for six to nine months following the procedure to assess symptoms, drug compliance, and treadmill test and coronary angiography results, and to ascertain the incidence of restenosis. However, only 80 patients returned for follow-up and, therefore, the final analysis was based on these patients. They were segregated into BMS (n=41) and DES (n=39) groups. Restenosis occurred in 29 patients (36.3%). Nine of 39 patients with DES (23.1%) and 20 of 41 patients with BMS (48.8%) developed restenosis. There was a statistically significant relationship between restenosis and female sex, clinical presentation before intervention and at the time of follow-up evaluation (unstable angina), hypertension, positive stress test and compliance with medical therapy (P0.05). CONCLUSIONS: DES appear to reduce the restenosis rate and clinical end points, and appear to be more cost effective than BMS. Patient-related factors (eg, sex, hypertension and unstable angina) are important variables that affect the restenosis rate. Noninvasive stress testing had high positive and negative predictive values. Therefore, based on the present study, noninvasive stress testing is suggested before routine angiography at follow-up, which will reduce the need for repeat coronary angiography.
Mohan et al. (Tue,) conducted a cohort in Coronary artery disease requiring stent implantation (n=130). Drug-eluting stents vs. Bare metal stents was evaluated on Restenosis. Drug-eluting stents were associated with a lower rate of restenosis compared to bare metal stents (23.1% vs 48.8%) at 6 to 9 months follow-up.